Loading...
Loading...
DYAI| Name | Value |
|---|---|
| Revenues | 879.6K |
| Cost of Revenue | 602.8K |
| Gross Profit | 276.8K |
| Operating Expense | 2,127.0K |
| Operating I/L | -1,863.5K |
| Other Income/Expense | 54.3K |
| Interest Income | 54.3K |
| Pretax | -1,809.2K |
| Income Tax Expense | -108.6K |
| Net Income/Loss | -1,700.6K |
Dyadic International, Inc. is a biotechnology platform company that develops, produces, and sells enzymes and other proteins in the United States. The company utilizes its patented C1 platform and other technologies for research, development, and commercial activities related to human and animal vaccines and drugs, including virus-like particles, monoclonal antibodies, and therapeutic enzymes. Its product portfolio includes the DYAI-100 SARS-CoV-2-RBD antigen vaccine candidate, aimed at a first-in-human Phase 1 clinical trial, and next-generation multivariant COVID-19 vaccine candidates. Dyadic International, Inc. generates revenue through the sale of its proprietary enzymes, proteins, and vaccine candidates.
